Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
8.87
Nov 03 • 3:59 PM ET Dollar change+0.32 Percentage change(3.74%)
Aftermarket Close
8.87
Aftermarket • 7:57 PM ET Dollar change-0.00 Percentage change(-0.02%)
Index
RUT
Market Cap
1.79B
Enterprise Value
1.65B
Income
-32.46M
Sales
0.00M
Book/sh
0.68
Cash/sh
0.69
Employees
13
IPO
Mar 12, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
13.01
P/C
12.94
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
18.83
Current Ratio
18.83
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.21
EPS next Y
-0.10
EPS next Q
-0.05
EPS this Y
18.00%
EPS next Y
53.66%
EPS next 5Y
-
EPS past 3/5Y
51.28% 34.92%
Sales past 3/5Y
- -
EPS Y/Y TTM
35.38%
Sales Y/Y TTM
-
EPS Q/Q
24.18%
Sales Q/Q
-
Insider Own
1.11%
Insider Trans
0.00%
Inst Own
36.93%
Inst Trans
10.16%
ROA
-36.54%
ROE
-39.63%
ROIC
-23.55%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-19.51%
SMA50
-25.53%
SMA200
2.90%
Trades
Shs Outstand
201.92M
Shs Float
199.70M
52W High
15.88 -44.13%
52W Low
1.39 538.13%
Volatility
13.59% 9.19%
ATR (14)
1.01
RSI (14)
36.14
Beta
2.72
Rel Volume
0.74
Avg Volume
6.79M
Volume
5,052,996
Perf Week
-27.12%
Perf Month
-23.73%
Perf Quarter
-25.21%
Perf Half Y
82.14%
Perf YTD
135.28%
Perf Year
395.53%
Perf 3Y
823.96%
Perf 5Y
-3.48%
Perf 10Y
-99.83%
Prev Close
8.55
Price
8.87
Change %
3.74%
Consensus
Strong Buy
Avg. Price Target
$32.50
Implied Upside
+266.4%
Analysts4incl. previous ratings
Rating Distribution4 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 21, 2021Initiated
CCantor Fitzgerald
Overweight$18+102.9%
Nov 01, 2018Initiated
OPY logoOOppenheimer
Outperform
Apr 02, 2018Initiated
HH.C. Wainwright
Buy$11+24.0%
Mar 19, 2018Upgrade
MMaxim Group
Hold → Buy$13+46.6%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kalin Katherine BachDirectorNov 19 '25Buy1.5963,400100,806104,400Nov 21 08:45 AM
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.
ScD h.c.Dr. Angelos M. Stergiou M.D.
Senior VP & CFOMr. John Thomas Burns CPA
MBADr. Dragan Cicic M.D.
VPMs. Stacy E. Yeung
Senior VP of Regulatory AffairsMr. Andrew Elnatan